Filament’s industry-leading IP portfolio now consists of ten patents for strategies of extracting and standardizing pure psychedelic compounds
VANCOUVER, BC, Nov. 30, 2022 /CNW/ – Filament Well being Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage pure psychedelic drug improvement firm, at the moment introduced that it has been issued two new patents for the extraction and standardization of pure psilocybin and related psychedelic compounds. Filament’s newest patents had been issued by the US Patent and Trademark Workplace (USPTO) and describe expertise for reworking variable psychedelic uncooked supplies into pharmaceutical-grade, standardized drug candidates.
“When Filament was founded, conventional wisdom held that producing stable psilocin was impossible,” stated Taran Gray, Director of Mental Property. “We have since been granted patent protection for successful production of psilocin at all stages of manufacture: from extraction to purification to standardization and beyond. For example, our latest issued patents around noningestive administration are demonstrable evidence of our team’s talent for innovation. The fact that we have never had a patent application denied, compared to the industry average of a less than 50% success rate, is further validation of this talent.”
Filament has developed progressive expertise to extract and standardize secure doses of pure compounds from magic mushrooms. On August 3, 2021, Filament was issued the first-ever patent for the extraction and standardization of pure psilocybin. Since then, the Firm has been issued a complete of 5 patents by the USPTO and 5 by the Canadian Mental Property Workplace.
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Well being is a clinical-stage pure psychedelic drug improvement firm. We imagine that protected, standardized, naturally-derived psychedelic medicines can enhance the lives of many, and our mission is to see them within the palms of everybody who wants them as quickly as potential. Filament’s platform of proprietary mental property allows the invention, improvement, and supply of pure psychedelic medicines. We’re paving the best way with the first-ever pure psychedelic drug candidates.
Be taught extra at www.filament.well being and on Twitter, Instagram and LinkedIn.
FORWARD LOOKING INFORMATION
Sure statements and data contained herein might represent “forward-looking statements” and “forward-looking information,” respectively, underneath Canadian securities laws. Usually, forward-looking data might be recognized by means of forward-looking terminology reminiscent of, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and related expressions are meant to establish forward-looking statements or data. The forward-looking statements usually are not historic info, however replicate the present expectations of administration of Filament relating to future outcomes or occasions and are based mostly on data presently accessible to them. Sure materials elements and assumptions had been utilized in offering these forward-looking statements. The forward-looking statements mentioned on this press launch might embody, however usually are not restricted to, data in regards to the affect of the patent on the Firm’s enterprise and the flexibility of the Firm to safe future patents. Ahead-looking statements relating to the Firm are based mostly on the Firm’s estimates and are topic to identified and unknown dangers, uncertainties and different elements that will trigger the precise outcomes, ranges of exercise, efficiency or achievements of Filament to be materially totally different from these expressed or implied by such forward-looking statements or forward-looking data, together with standing of patent purposes and the flexibility to safe patents. There might be no assurance that such statements will show to be correct, as precise outcomes and future occasions might differ materially from these anticipated in such statements. Accordingly, readers shouldn’t place undue reliance on forward-looking statements and forward-looking data. Filament is not going to replace any forward-looking statements or forward-looking data which are included by reference herein, besides as required by relevant securities legal guidelines.
SOURCE Filament Well being Corp.
For additional data: MEDIA RELATIONS: Anna Cordon, Director of Communications, 778.245.9067, [email protected]; INVESTOR RELATIONS: [email protected]